Literature DB >> 16733203

Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications.

Muna Sabah1, Robert Cummins, Mary Leader, Elaine Kay.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract. The prediction of the malignant potential of GISTs is still difficult. Altered cell cycle regulation may underlie the tumorigenesis and/or the progression of human malignancies. Although p53 and Bcl-2 have been extensively investigated in GISTs, little is known about the frequency of expression and possible clinical implications of alterations of other cell cycle regulatory proteins in these neoplasms. We have previously investigated the role of loss of p16(INK4A) by loss of heterozygosity and immunohistochemistry in the progression of GISTs and found that loss of heterozygosity of 9p and loss of p16 expression are confined to malignant GISTs. This has led us to investigate the role of other cell cycle regulatory proteins in these tumors. Twenty-three cases of GIST (9 low malignant potential [LMP], 10 primary malignant, and 4 intra-abdominal recurrences) were examined. All cases were strongly positive for KIT (CD117). Immunohistochemical stains were carried out on tissue microarrays to evaluate the expression of proteins involved in the G(1)-S transition and proteins that regulate apoptosis including Rb, E2F1, cyclin D1, CDK4, CDK6, p27(KIP1), p21(WAF1/CIP1), p53, Mdm2, Bcl-2, and Bax. The positive phenotypes identified were as follows: Rb, 39.1%; E2F1, 69.6%; cyclin D1, 30.4%; CDK4, 100%; CDK6, 30.4%; 39.1%; p27(KIP1), 47.8%; p21(WAF1/CIP1), 39.1%; p53, 43.5%; Mdm2, 17.4%; Bcl-2, 91.3%; and Bax, 100%. Malignant GISTs are more likely to be associated with a positive E2F1 and p53 phenotype and a negative p16 and p27(KIP1) phenotype. It was concluded that aberration of the cell cycle regulators is a frequent finding and may be a contributing factor to the pathogenesis of GISTs. While some alterations are seen in LMP and malignant GISTs and therefore may represent an early event in molecular tumorigenesis of GISTs, other alterations are more common in malignant GISTs than LMP and therefore have potential utility as complementary tools for the prognostication of GISTs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733203     DOI: 10.1016/j.humpath.2006.01.023

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  PDL1 expression is an independent prognostic factor in localized GIST.

Authors:  François Bertucci; Pascal Finetti; Emilie Mamessier; Maria Abbondanza Pantaleo; Annalisa Astolfi; Jerzy Ostrowski; Daniel Birnbaum
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

2.  Prognostic value of E2F1 in rectal cancer.

Authors:  Hasan Uzer; Hızır Akyıldız; Erdoğan Sözüer; Alper Akcan; Bahadır Öz
Journal:  Turk J Surg       Date:  2017-09-01

3.  p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome.

Authors:  Michael Schmieder; Sebastian Wolf; Bettina Danner; Susanne Stoehr; Markus S Juchems; Peter Wuerl; Doris Henne-Bruns; Uwe Knippschild; Cornelia Hasel; Klaus Kramer
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

4.  Predictive value of p53 expression in the risk of malignant gastrointestinal stromal tumors: Evidence from 19 studies.

Authors:  Liang Zong; Ping Chen; Jian Jiang; Lei Wang; Qing Guo Li
Journal:  Exp Ther Med       Date:  2011-10-19       Impact factor: 2.447

5.  High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.

Authors:  Martin G Belinsky; Yuliya V Skorobogatko; Lori Rink; Jianming Pei; Kathy Q Cai; Lisa A Vanderveer; David Riddell; Erin Merkel; Chi Tarn; Burton L Eisenberg; Margaret von Mehren; Joseph R Testa; Andrew K Godwin
Journal:  Genes Chromosomes Cancer       Date:  2009-10       Impact factor: 5.006

6.  Cyclin H expression is increased in GIST with very-high risk of malignancy.

Authors:  Julian Dorn; Hanno Spatz; Michael Schmieder; Thomas Fe Barth; Annette Blatz; Doris Henne-Bruns; Uwe Knippschild; Klaus Kramer
Journal:  BMC Cancer       Date:  2010-07-02       Impact factor: 4.430

7.  Gastrointestinal stromal tumor of the anal canal: an unusual presentation.

Authors:  Giuseppe R Nigri; Mario Dente; Stefano Valabrega; Paolo Aurello; Francesco D'Angelo; Giuseppe Montrone; Giorgio Ercolani; Giovanni Ramacciato
Journal:  World J Surg Oncol       Date:  2007-02-16       Impact factor: 2.754

8.  Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours.

Authors:  Dolores Di Vizio; Francesca Demichelis; Sara Simonetti; Guido Pettinato; Luigi Terracciano; Luigi Tornillo; Michael R Freeman; Luigi Insabato
Journal:  BMC Cancer       Date:  2008-05-13       Impact factor: 4.430

9.  Genomic Grade Index predicts postoperative clinical outcome of GIST.

Authors:  F Bertucci; P Finetti; J Ostrowski; W K Kim; H Kim; M A Pantaleo; A Astolfi; M Polkowski; D Birnbaum
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

10.  P53 expression is significantly correlated with high risk of malignancy and epithelioid differentiation in GISTs. An immunohistochemical study of 104 cases.

Authors:  Ursula Pauser; Nina Schmedt Auf der Günne; Günter Klöppel; Hartmut Merz; Alfred C Feller
Journal:  BMC Cancer       Date:  2008-07-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.